A. Oge et al., Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin, J CHEMOTHER, 12(1), 2000, pp. 105-108
Severe nausea and vomiting are common and one of the most feared side effec
ts of cisplatin-based chemotherapy, A total of 106 patients were randomized
to receive a single dose of 8 mg ondansetron or 3 mg granisetron or 5 mg t
ropisetron intravenously as prevention of cisplatin-induced acute nausea an
d vomiting. Antiemetic therapy was done within 30 minutes before initiating
chemotherapy. A questionnaire evaluating nausea, vomiting and retches was
administered to patients and the responses were categorized as complete, pa
rtial or failure. The response determination was repeated in the first 24 h
ours, and within 24-72 hours following cisplatin administration.
The complete response rates for ondansetron, granisetron and tropisetron in
the first 24 hours were 51.4%, 65.7% and 61.1% respectively, All three age
nts were highly effective against cisplatin-induced acute and late vomiting
and the results were statistically significant. This study demonstrated no
significant difference in effectiveness of these three antiemetics. 5-HT3
(5-hydroxytryptamine 3) receptor antagonists have similar efficacy in the p
revention of nausea and vomiting due to cisplatin. Thus, we recommend that
drug choice be based on cost-benefit and patient tolerance.